133 related articles for article (PubMed ID: 31759686)
1. Five-year clinical outcome of multicenter randomized trial comparing amphilimus - with paclitaxel-eluting stents in de novo native coronary artery lesions.
Carrié D; Berland J; Verheye S; Hauptmann KE; Vrolix M; Musto C; Berti S; Dibié A; Maupas E; Antoniucci D; Schofer J
Int J Cardiol; 2020 Feb; 301():50-55. PubMed ID: 31759686
[TBL] [Abstract][Full Text] [Related]
2. A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions.
Carrié D; Berland J; Verheye S; Hauptmann KE; Vrolix M; Violini R; Dibie A; Berti S; Maupas E; Antoniucci D; Schofer J
J Am Coll Cardiol; 2012 Apr; 59(15):1371-6. PubMed ID: 22284328
[TBL] [Abstract][Full Text] [Related]
3. 10-Year Outcomes From a Randomized Trial of Polymer-Free Versus Durable Polymer Drug-Eluting Coronary Stents.
Kufner S; Ernst M; Cassese S; Joner M; Mayer K; Colleran R; Koppara T; Xhepa E; Koch T; Wiebe J; Ibrahim T; Fusaro M; Laugwitz KL; Schunkert H; Kastrati A; Byrne RA;
J Am Coll Cardiol; 2020 Jul; 76(2):146-158. PubMed ID: 32646563
[TBL] [Abstract][Full Text] [Related]
4. Five-year clinical follow-up of a randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus (LIPSIA Yukon trial).
Stiermaier T; Heinz A; Schloma D; Kleinertz K; Dänschel W; Erbs S; Linke A; Boudriot E; Lauer B; Schuler G; Thiele H; Desch S
Catheter Cardiovasc Interv; 2014 Feb; 83(3):418-24. PubMed ID: 23873579
[TBL] [Abstract][Full Text] [Related]
5. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
[TBL] [Abstract][Full Text] [Related]
6. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Polymer-Free Drug-Eluting Stents.
Chiarito M; Sardella G; Colombo A; Briguori C; Testa L; Bedogni F; Fabbiocchi F; Paggi A; Palloshi A; Tamburino C; Margonato A; Pivato CA; Baber U; Calcagno S; Giordano A; Godino C; Stefanini GG
Circ Cardiovasc Interv; 2019 Feb; 12(2):e007311. PubMed ID: 30767663
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcomes of real-world patients treated with an amphilimus polymer-free stent versus new generation everolimus-eluting stents.
Panoulas VF; Latib A; Naim C; Sato K; Ielasi A; Tespili M; Godino C; Testa L; Bedogni F; Colombo A
Catheter Cardiovasc Interv; 2015 Dec; 86(7):1168-76. PubMed ID: 26269415
[TBL] [Abstract][Full Text] [Related]
9. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
10. The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent.
Haude M; Lee SW; Worthley SG; Silber S; Verheye S; Erbs S; Rosli MA; Botelho R; Meredith I; Sim KH; Stella PR; Tan HC; Whitbourn R; Thambar S; Abizaid A; Koh TH; Den Heijer P; Parise H; Cristea E; Maehara A; Mehran R
JACC Cardiovasc Interv; 2013 Apr; 6(4):334-43. PubMed ID: 23523459
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: the LIPSIA Yukon trial.
Desch S; Schloma D; Möbius-Winkler S; Erbs S; Gielen S; Linke A; Yu J; Lauer B; Kleinertz K; Dänschel W; Schuler G; Thiele H
JACC Cardiovasc Interv; 2011 Apr; 4(4):452-9. PubMed ID: 21511226
[TBL] [Abstract][Full Text] [Related]
12. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
Kirtane AJ; Leon MB; Ball MW; Bajwa HS; Sketch MH; Coleman PS; Stoler RC; Papadakos S; Cutlip DE; Mauri L; Kandzari DE;
JACC Cardiovasc Interv; 2013 Apr; 6(4):325-33. PubMed ID: 23523453
[TBL] [Abstract][Full Text] [Related]
13. Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions: 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial.
Costa RA; Abizaid A; Mehran R; Schofer J; Schuler GC; Hauptmann KE; Magalhães MA; Parise H; Grube E;
JACC Cardiovasc Interv; 2016 Jan; 9(1):51-64. PubMed ID: 26762911
[TBL] [Abstract][Full Text] [Related]
14. First-in-man randomised comparison of the BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: the PIONEER trial.
von Birgelen C; Asano T; Amoroso G; Aminian A; Brugaletta S; Vrolix M; Hernandez-Antolín R; van de Harst P; Iñiguez A; Janssens L; Smits PC; Wykrzykowska JJ; Ribeiro VG; Pereira H; da Silva PC; Piek JJ; Onuma Y; Serruys PW; Sabaté M
EuroIntervention; 2018 Apr; 13(17):2026-2035. PubMed ID: 28923787
[TBL] [Abstract][Full Text] [Related]
15. Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial.
Romaguera R; Salinas P; Gomez-Lara J; Brugaletta S; Gómez-Menchero A; Romero MA; García-Blas S; Ocaranza R; Bordes P; Kockar MJ; Salvatella N; Jiménez-Díaz VA; Alameda M; Trillo R; Lee DH; Martín P; López-Benito M; Freites A; Pascual-Tejerina V; Hernández-Hernández F; Blanco BGD; Mohandes M; Bosa F; Pinar E; Roura G; Comin-Colet J; Fernández-Ortiz A; Macaya C; Rossello X; Sabate M; Pocock SJ; Gómez-Hospital JA;
Eur Heart J; 2022 Mar; 43(13):1320-1330. PubMed ID: 34735004
[TBL] [Abstract][Full Text] [Related]
16. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of Zotarolimus- vs. Paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries: five-year results from the ZOMAXX I trial.
Chevalier B; Dimario C; Neumann FJ; Cutlip DE; Williams DO; Ormiston J; Grube E; Whitbourn R; Coe J; Schwartz LB;
Catheter Cardiovasc Interv; 2013 Dec; 82(7):1039-47. PubMed ID: 23592567
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
18. Rationale and study design of the RESERVOIR trial: a randomized trial comparing reservoir-based polymer-free amphilimus-eluting stents versus everolimus-eluting stents with durable polymer in patients with diabetes mellitus.
Romaguera R; Brugaletta S; Gomez-Lara J; Pinar E; Jiménez-Quevedo P; Gracida M; Roura G; Ferreiro JL; Teruel L; Gómez-Hospital JA; Montanya E; Alfonso F; Valgimigli M; Sabate M; Cequier A
Catheter Cardiovasc Interv; 2015 Mar; 85(4):E116-22. PubMed ID: 25380051
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes with reservoir-based polymer-free amphilimus-eluting stents in real-world patients according to diabetes mellitus and complexity: The INVESTIG8 registry.
Sardella G; Stella P; Chiarito M; Leone AM; Balian V; Prosperi F; Sorropago G; Mancone M; Calcagno S; Briguori C; Stefanini GG
Catheter Cardiovasc Interv; 2018 Apr; 91(5):884-891. PubMed ID: 28707375
[TBL] [Abstract][Full Text] [Related]
20. One-year clinical outcome of amphilimus polymer-free drug-eluting stent in diabetes mellitus patients: Insight from the ASTUTE registry (AmphilimuS iTalian mUlticenTre rEgistry).
Colombo A; Godino C; Donahue M; Testa L; Chiarito M; Pavon AG; Colantonio R; Cappelletti A; Monello A; Magni V; Milazzo D; Parisi R; Nicolino A; Moshiri S; Fattori R; Aprigliano G; Palloshi A; Caramanno G; Montorfano M; Bedogni F; Margonato A; Briguori C
Int J Cardiol; 2016 Jul; 214():113-20. PubMed ID: 27060269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
